Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00367 JCO Precision Oncology no. 6 (2022) e2200367. Published online October 6, 2022. PMID: 36201715 Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment Marcelo Corassa , MD1xMarcelo CorassaSearch for articles by this author; Rodrigo Fonseca Abreu , MD2xRodrigo Fonseca AbreuSearch for articles by this author; Vladmir Claudio Cordeiro de Lima , MD, PhD1xVladmir Claudio Cordeiro de LimaSearch for articles by this author; Giovana Tardim Torrezan , PhD3,4xGiovana Tardim TorrezanSearch for articles by this author; Felicia Peterson Cavalher, MD, PhD1xFelicia Peterson CavalherSearch for articles by this author; Tullio Novaes Silva, MD2xTullio Novaes SilvaSearch for articles by this author; Thiago Bueno de Oliveira , MD, PhD1xThiago Bueno de OliveiraSearch for articles by this author; Helano Carioca Freitas , MD, PhD1xHelano Carioca FreitasSearch for articles by this author; Dirce Maria Carraro , PhD3,4xDirce Maria CarraroSearch for articles by this author; and Felipe D'Almeida Costa, MD, PhD2xFelipe D'Almeida CostaSearch for articles by this author Show More 1Medical Oncology Department, A.C. Camargo Cancer Center, R. Professor Antonio Prudente, São Paulo, Brazil2Department of Pathology, R. Professor Antonio Prudente, São Paulo, Brazil3Genomics and Molecular Biology Group, International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo, Brazil4National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo, Brazil https://doi.org/10.1200/PO.22.00367 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Marcelo Corassa, Rodrigo Fonseca Abreu, Tullio Novaes Silva, Thiago Bueno de Oliveira, Helano Carioca Freitas, Felipe D'Almeida CostaFinancial support: Dirce Maria CarraroProvision of study materials or patients: Vladmir Claudio Cordeiro de Lima, Tullio Novaes SilvaCollection and assembly of data: Marcelo Corassa, Rodrigo Fonseca Abreu, Felicia Peterson Cavalher, Tullio Novaes SilvaData analysis and interpretation: Marcelo Corassa, Rodrigo Fonseca Abreu, Vladmir Claudio Cordeiro de Lima, Giovana Tardim Torrezan, Tullio Novaes Silva, Thiago Bueno de Oliveira, Helano Carioca Freitas, Dirce Maria CarraroManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Marcelo CorassaHonoraria: AstraZeneca, MSD, Bristol Myers Squibb Brazil, Janssen, Lilly, Takeda, Amgen, Sanofi/Regeneron, Novartis, PfizerConsulting or Advisory Role: AstraZeneca, Bristol Myers Squibb, TakedaSpeakers' Bureau: Takeda, AstraZeneca, Bristol Myers Squibb, MSD, JanssenVladmir Claudio Cordeiro de LimaConsulting or Advisory Role: BMS Brazil, AstraZeneca, MSD, Lilly, Pfizer, Janssen, Daiichi-Sankyo, AmgenSpeakers' Bureau: BMS Brazil, MSD, Lilly, Novartis, AstraZeneca/Daiichi SankyoResearch Funding: BMS (Inst)Travel, Accommodations, Expenses: MSD, AstraZeneca, Boehringer Ingelheim, BMS BrazilGiovana Tardim TorrezanSpeakers' Bureau: Roche Molecular DiagnosticsFelicia Peterson CavalherTravel, Accommodations, Expenses: AmgenThiago Bueno de OliveiraConsulting or Advisory Role: MSD Oncology, BMS Brazil, AstraZeneca, Janssen Oncology, United MedicalSpeakers' Bureau: MSD Oncology, BMS Brazil, AstraZeneca, Janssen Oncology, Merck Serono, SanofiResearch Funding: MSD OncologyTravel, Accommodations, Expenses: MSD Oncology, Janssen OncologyHelano Carioca FreitasEmployment: BMS BrazilStock and Other Ownership Interests: BMS BrazilConsulting or Advisory Role: MSD, Takeda, Roche, Novartis, LillySpeakers' Bureau: MSD, AstraZeneca, Roche, Pfizer, Amgen, BMS Brazil, TakedaTravel, Accommodations, Expenses: Takeda, MSDNo other potential conflicts of interest were reported.